{
 "OTHER": [
  "TOBACCO_USE_DISORDER",
  "INTERSTITIAL_INFLAMMATORY_CELL_INFILTRATION",
  "SPONTANEOUS_HCV_CLEARANCE",
  "OPIOID-RELATED_DISORDERS",
  "DECREASED_GLOMERULAR_FILTRATION_RATE",
  "DISCONTINUATION",
  "TREATMENT_MODIFICATION",
  "P2Y12_REACTION_UNIT(PRU)_VALUES",
  "PLATELET_REACTIVITY_BY_P2Y12_REACTION_UNITS",
  "PERCENTAGE_OF_DAYS_ABSTINENT_AND_LOWER_NUMBER_OF_DRINKS_PER_DRINKING_DAY",
  "ATOPY_IN_PATIENTS_WITH_ASPIRIN-INTOLERANT_CHRONIC_URTICARIA",
  "SMOKING_CESSATION",
  "IN-STENT_RESTENOSIS",
  "CREATININE_CLEARANCE",
  "INTAKE",
  "HMGCRV_1_EXPRESSION_AND_AN_INCREASE_IN_THE_EXPRESSION_OF_THE_FULL-LENGTH_TRANSCRIPT",
  "SERUM_AND_RED_BLOOD_CELL_FOLATE_CONCENTRATIONS",
  "ALCOHOL_ABUSE",
  "COCAINE_DEPENDENCE",
  "COVID-19",
  "TIME_TO_THERAPEUTIC_INR",
  "DEATH",
  "REMAINING_ON_STEROIDS_AT_1_YEAR_AFTER_TRANSPLANTATION",
  "INTRAGASTRIC_PH",
  "HIGHER_STABLE_DOSE_LEVELS",
  "METHAMPHETAMINE_DEPENDENCE",
  "ADVERSE_CARDIOVASCULAR_OUTCOMES",
  "ASTHMA",
  "PROTECTION_AGAINST_SEVERE_MALARIA",
  "RECURRENCE",
  "USE",
  "HAVING_WARFARIN_DOSE_GREATER_THAN_7.5_MG/DAY",
  "OSTEOPOROTIC_FRACTURE",
  "TUBULAR_VACUOLAR_DEGENERATION",
  "QT_INTERVAL",
  "DISEASE_RECURRENCE",
  "SIGNIFICANTLY_HIGHER_TRAMADOL_CONSUMPTION_IN_CHINESE_GASTRIC_CANCER_PATIENTS_RECOVERING_FROM_GASTRECTOMY",
  "WARFARIN_DOSE_IN_KOREAN_PATIENTS_WITH_MECHANICAL_HEART_VALVE_REPLACEMENT_SINCE_DAY_7_OF_WARFARIN_THERAPY",
  "HEROIN_DEPENDENCE",
  "ALCOHOL_RESPONSE",
  "PLATELET_REACTIVITY",
  "WARFARIN_DOSE_REQUIREMENT",
  "GILBERT_SYNDROME",
  "CRIGLER-NAJJAR_SYNDROME",
  "WARFARIN_DOSE",
  "REDUCTIONS_IN_GLUTATHIONE_LEVELS",
  "HYDROCHLOROTHIAZIDE_INDUCED_POTASSIUM_EXCRETION",
  "WEIGHT_REGAIN_AFTER_INTENTIONAL_WEIGHT_LOSS",
  "SENSITIVITY_IN_VITRO",
  "OVERANTICOAGULATION",
  "INOSINE_MONOPHOSPHATE_DEHYDROGENASE_ACTIVITY",
  "EVENT-FREE_SURVIVAL",
  "SUBSTANCE-RELATED_DISORDERS",
  "ADENOMATOUS_AND_HYPERPLASTIC_POLYPS",
  "RECURRENCE_FREE_SURVIVAL",
  "NON-FATAL_MYOCARDIAL_INFARCTION",
  "LYMPH_NODE_INVOLVEMENT",
  "PLASMA_LEVEL",
  "WAKEFULNESS_ACTIVITY_LEVEL",
  "TUMOR_SIZE",
  "METASTATIC_NEOPLASM",
  "BASELINE_VIRAL_LOAD",
  "INOS_EXPRESSION",
  "PLASMA_CONCENTRATION_OF_S-DIDESMETHYL-CITALOPRAM",
  "PAIN",
  "CONCENTRATIONS_OF_S-CITALOPRAM_AND_METABOLIC_RATIO_OF_OF_S-DESMETHYLCITALOPRAM/CITALOPRAM",
  "GREATER_HEART_RATE_(HR)_REDUCTION",
  "HIGH_PLATELET_REACTIVITY_(HPR)",
  "A_CORRELATION_OF_BRAIN_SERT_OCCUPANCY_WAS_ASSOCIATED_WITH_LARGER_PROPORTIONAL_HDRS17_DECREASES",
  "BONE_MARROW_DENSITY_IN_THE_LUMBAR_SPINE",
  "DISEASE-FREE_SURVIVAL",
  "METHYLATION_AT_SITES_1_AND_2_IN_THE_COMT_PROMOTER",
  "GASTRIC_PH",
  "OVERALL_SURVIVAL",
  "BLOOD_COAGULATION_DISORDERS",
  "HEART_RATE_(HR)_AND_DIASTOLIC_BLOOD_PRESSURE_(DBP)_REDUCTIONS_DURING_EARLY_TITRATION",
  "INHIBITION_OF_CYP3A-CATALYZED_METABOLISM_OF_MIDAZOLAM_OR_TESTOSTERONE",
  "WEIGHT",
  "CIGARETTES_PER_DAY",
  "WARFARIN_DOSE_IN_JAPANESE_PATIENTS",
  "HOSPITAL_STAY",
  "COMPLICATIONS",
  "WARFARIN_DOSE_AFTER_ADJUSTMENT_FOR_VKORC1*1173",
  "MEAL-STIMULATED_PLASMA_GASTRIN_CONCENTRATIONS",
  "OROCECCAL_TRANSIT_TIME",
  "ERYTHROMYCIN_TRANSPORT",
  "SENSITIVITY_TO_ETOPOSIDE",
  "LEVEL_OF_APOLIPOPROTEIN_A1",
  "LEVELS_OF_VITAMIN_K-DEPENDENT_PROTEINS",
  "TOTAL_CHOLESTEROL",
  "ASTHMA_EXACERBATIONS",
  "RECURRENCE-FREE_SURVIVAL",
  "SUBCLINICAL_ACUTE_REJECTION",
  "LONGER_TITRATION_TO_ACHIEVE_OPTIMAL_BENEFIT",
  "DRUG_DOSAGE_ALTERED",
  "MAJOR_ADVERSE_CARDIAC_EVENTS",
  "CARDIOVASCULAR_DEATH",
  "DEPENDENCE",
  "METABOLIC_RATIO_DEM/DOR",
  "COFFEE_CONSUMPTION",
  "NON-SMALL_CELL_LUNG_CARCINOMA",
  "SIGNIFICANTLY_SHORTER_SURVIVAL",
  "PLATELET_AGGREGATION_WITH_ADP",
  "NEONATAL_HYPERBILIRUBINEMIA",
  "HDL_CHOLESTEROL",
  "HABITUAL_CONSUMPTION",
  "STOP_REACTION_TIME",
  "WARFARIN_SENSITIVITY_INDEX_(INR/CPSS)",
  "MAJOR_ADVERSE_CARDIOVASCULAR_EVENTS",
  "SPINE_BONE_MINERAL_DENSITY",
  "BETTER_SURVIVAL_OUTCOME",
  "WARFARIN_VARIABILITY",
  "STIMULATION_AND_EUPHORIA_SCORES_AFTER_AMPHETAMINE",
  "BONE_MINERAL_DENSITY",
  "LUMBAR_SPINE_BONE_MINERAL_DENSITY",
  "EUPHORIC_AND_ENERGETIC_AFTER_AMPHETAMINE_(10_MG)",
  "5%_LOWER_ADP-INDUCED_PEAK_PLATELET_AGGREGATION_IN-VITRO",
  "SICKLE_CELL_PAIN_CRISIS",
  "CHRONIC_LUNG_ALLOGRAFT_DYSFUNCTION",
  "TRANSPLANT_REJECTION",
  "SHORT_AND_LONG-TERM_WEIGHT_LOSS",
  "HELICOBACTER_PYLORI_INFECTION",
  "ADP-STIMULATED_PLATELET_AGGREGATION",
  "HYPERURICEMIA",
  "HYPERTRIGLYCERIDEMIA",
  "MORTALITY_AFTER_MYOCARDIAL_INFARCTION",
  "DEXMEDETOMIDINE_ED50_VALUES_FOR_DRUG-INDUCED_DORSAL_HAND_VEIN_(DHV)_CONSTRICTION",
  "PROTECTION_FROM_PLASMODIUM_VIVAX_MALARIA_INFECTION",
  "SYSTOLIC_(SAP)_AND_DIASTOLIC_(DAP)_ARTERIAL_PRESSURE_RESPONSES_TO_TIMOLOL",
  "PROTECTION_AGAINST_SEVERE_(P=0.006)_AND_MILD_MALARIA_(P=0.027)",
  "SAME_PROTECTIVE_PROPERTIES_AGAINST_ANGIOTENSIN-CONVERTING_ENZYME_INHIBITORS-INDUCED_COUGH",
  "PROTECTION_AGAINST_DEVELOPING_SEVERE_MALARIA",
  "RECURRENT_PREGCY_LOSS",
  "ASPIRIN-INTOLERANT_ASTHMA",
  "STABLE_WARFARIN_DOSE",
  "WARFARIN_DOSE_DURING_3-MONTH_DAILY_OBSERVATION_PERIOD_IN_PATIENTS_WITH_MECHANICAL_HEART_VALVE_REPLACEMENT",
  "BIOCHEMICAL_RESPONSE",
  "ALL-CAUSE_MORTALITY",
  "STATIN_DOSES_FOR_OPTIMAL_LIPID_CONTROL",
  "HYDROCHLOROTHIAZIDE_INDUCED_CALCIUM_RETENTION",
  "WHOLE_BLOOD_NITRITE",
  "ERYTHROCYTE_PLASMA_MEMBRANE_FLUIDITY",
  "ABSTINENCE",
  "SMALL-DENSE_LDL_LEVELS",
  "EXPRESSION_OF_ENZYME_CONTRIBUTING_TO_THE_METABOLISM",
  "PRE-ECLAMPSIA",
  "PLATELET_AGGREGATION_WITH_EPINEPHRINE",
  "SMOKING",
  "20%_AND_17%_LESS_INHIBITION_OF_PLATELET_AGGREGATION_WITH_CRANGRELOR_(0.05_AND_0.25_MICROM)_IN-VITRO",
  "ASPIRIN-INDUCED_ASTHMA",
  "DOSE_DECREASE_OR_DRUG_SWITCHING",
  "ACE_ACTIVITY",
  "OXIDATIVE_STRESS",
  "EMERGENCY_DEPARTMENT_AND_HOSPITAL_UTLIIZATION",
  "EMERGENCY_DEPARTMENT_UTLIIZATION",
  "EMERGENCIES",
  "ACUTE_REJECTION",
  "DOWN_SYNDROME",
  "PROLACTIN",
  "TACROLIMUS_NEPHROTOXICITY",
  "SUBCLINICAL_ALLOGRAFT_NEPHROPATHY",
  "MAINTECE_DOSE_OF_WARFARIN",
  "SUBSTANCE_WITHDRAWAL_SYNDROME",
  "A_MORE_RAPID_ATTAINMENT_OF_TARGET_INR_AND_HIGHER_FREQUENCY_OF_DOSE_ADJUSTMENTS",
  "CARDIOVASCULAR_EVENTS",
  "CARDIAC_REHOSPITALIZATION",
  "ATTENTION_DEFICIT_DISORDER_WITH_HYPERACTIVITY",
  "LEVELS_OF_IGG",
  "DIABETES_MELLITUS",
  "TIME_TO_TUMOR_RECURRENCE_(TTR)",
  "PROGRESSION-FREE_SURVIVAL",
  "PLASMA_LEVEL_OF_HIGH-SENSITIVITY_C-REACTIVE_PROTEIN",
  "BLOOD_PRESSURE",
  "SURVIVAL",
  "PRIMARY_OUTCOME",
  "NEONATAL_ABSTINENCE_SYNDROME",
  "ABSOLUTE_LEUCOCYTE_AND_NEUTROPHIL_COUNTS_ON_DAY_15",
  "ADDICTION",
  "LENGTH_OF_HOSPITAL_STAY",
  "TREATMENT",
  "ENDOGENOUS_LEVELS_OF_EPO",
  "SENSITIVE_TO_ANTILYMPHOCYTE_SERUM",
  "SENSITIVITY_TO_ASPIRIN",
  "MANIC_SYMPTOMS_IN_PSYCHOSIS",
  "SMOKING_QUANTITY",
  "SHORTER_BLEEDING_TIME",
  "HYPOGLYCEMIA",
  "BASELINE_PROINSULIN_LEVELS_AFTER_ADJUSTING_FOR_INSULIN_LEVELS",
  "SMOKING_INITIATION",
  "CURRENT_SMOKING",
  "CARDIAC_ARREST",
  "RESPIRATORY_INSUFFICIENCY",
  "WARFARIN_DOSE_REQUIREMENTS_ON_DAY_14",
  "HYPERBILIRUBINEMIA",
  "VITAMIN_D_DEFICIENCY",
  "WARFARIN_DOSE_REQUIREMENT_IN_MECHANICAL_HEART_VALVE_REPLACEMENT_PATIENTS",
  "PEAK_PLASMA_CONCENTRATION_OF_INCREASED_PROLACTIN",
  "CRAVING",
  "POST-TRAUMATIC_STRESS_DISORDER_(PTSD)",
  "CORONARY_FLOW_RESERVE",
  "ADENOSINE-STIMULATED_MYOCARDIAL_FLOW",
  "PREMATURE_BIRTH",
  "HEARING_LOSS",
  "ADVERSE_EVENTS",
  "HEART_RATE",
  "NICOTINE_DEPENDENCE",
  "BRAIN_ISCHEMIA",
  "MYOCARDIAL_INFARCTION",
  "PERIPHERAL_VASCULAR_DISEASES",
  "DIABETIC_RETINOPATHY",
  "CHRONIC_KIDNEY_FAILURE",
  "COLLAGEN-INDUCED_PLATELET_AGGREGATION",
  "EARLY_RELAPSE",
  "PHYSIOLOGICAL_SEXUAL_DISORDER",
  "NUMBER_OF_CIGARETTES_SMOKED_PER_DAY",
  "HIGH_ON-ASPIRIN_RESIDUAL_PLATELET_REACTIVITY",
  "OUTCOME_TIME_TO_STABLE_DOSE",
  "HIGH_PLATELET_REACTIVITY",
  "HEAVY_CONSUMPTION",
  "NEPHROTOXICITY",
  "FUNCTIONAL_MRI_REACTIVITY_TO_SMOKING_IMAGES",
  "SUICIDAL_IDEATION",
  "DISEASE_FREE_SURVIVAL",
  "LYMPH_NODE_METASTASIS",
  "REQUIRING_POSTOPERATIVE_INTERVENTION",
  "PLATELET_FUNCTION",
  "ELEVATED_CIRCULATING_CREATINE_KINASE_CONCENTRATION",
  "SOCIAL_WITHDRAWAL",
  "DISEASE-FREE_SURVIVAL_AND_OVERALL_SURVIVAL",
  "WORSE_OVERALL_SURVIVAL_OUTCOME",
  "CORTICAL_SILENT_PERIOD_DURATION",
  "SERUM_TOTAL_CHOLESTEROL",
  "SERUM_LDL",
  "DIABETES",
  "OSTEOARTHRITIS",
  "TOXIC_LIVER_DISEASE",
  "AMBULATORY_BLOOD_PRESSURE",
  "BONE_MINERAL_DENSITY_(BMD)",
  "SEVERE_EXACERBATIONS_WITH_ASTHMA",
  "OPIATE_WITHDRAWAL_SYMPTOMS",
  "BONE_MINERAL_DENSITY_AT_FEMORAL_NECK_AND_LUMBAR_SPINE",
  "BMD_VALUES_AT_THE_LUMBAR_SPINE_AND_FEMORAL_NECK",
  "SUBJECTIVE_FEELINGS_OF_INTOXICATION",
  "ALLELIC_IMBALENCE",
  "CHOLESTEROL_SYNTHESIS_RATE",
  "MEAN_ARTERIAL_PRESSURE",
  "STATUS_ASTHMATICUS",
  "NEOPLASMS",
  "LATER_ONSET_OF_SENSORY_NEUROPATHY",
  "PROGRESSION-FREE_SURVIVAL_AND_OVERALL_SURVIVAL",
  "VARIANCE_IN_LDL"
 ],
 "SIDE_EFFECT": [
  "NAUSEA",
  "SYSTOLIC_BLOOD_PRESSURE_AND_INCREASED_RISK_OF_DEVELOPING_GRADE_3_HYPERTENSION",
  "GRADE_3_HYPERTENSION",
  "NEUROLOGICAL_EVENTS",
  "ADVERSE_CARDIOVASCULAR_OUTCOMES",
  "HEMORRHAGE",
  "ADVERSE_EVENTS",
  "SIALOADENITIS",
  "DIZZINESS",
  "HEADACHE",
  "WEIGHT_GAIN",
  "ELEVATED_SYSTOLIC_BLOOD_PRESSURE",
  "HEART_RATE",
  "HEPATOCELLULAR_INJURY",
  "INCREASED_PULSE_RATE",
  "PAIN",
  "RENAL_PROXIMAL_TUBULOPATHY",
  "DYSPNEA",
  "DRUG_INDUCED_LIVER_INJURY",
  "EXTRAPYRAMIDAL_SYMPTOMS",
  "PARKINSONIAN_DISORDER",
  "BODY_WEIGHT_GAIN",
  "AGITATION",
  "GASTROINTESTINAL_BLEEDING",
  "ACUTE_GASTROINTESTINAL_BLEEDING",
  "LEUKOPENIA",
  "NEUTROPENIA",
  "MUCOSITIS",
  "WITHDRAWAL_EFFECTS",
  "ADVERSE_DRUG_EVENT",
  "DIARRHEA_WITHIN_24_HOURS_AND_THROMBOCYTOPENIA",
  "TIME_TO_DISCONTINUATION_OR_DOSE_REDUCTION",
  "ADVERSE_DRUG_EVENTS",
  "NECESSITY_TO_REDUCE_IRINOTECAN_DOSAGE",
  "AROUSAL_DYSFUNCTION",
  "ANEMIA",
  "IQ",
  "NEPHROTOXICITY",
  "SEVERE_MYELOSUPPRESSION",
  "DERMATOLOGIC_TOXICITY",
  "GRADE_III/IV_LIVER_TOXICITY",
  "HAND-FOOT_SYNDROME",
  "PERIPHERAL_NERVOUS_SYSTEM_DISEASES",
  "TRIGLYCERIDES_IN_POSTMENOPAUSAL_WOMAN",
  "IN_TOTAL_CHOLESTEROL_IN_POSTMENOPAUSAL_WOMAN_AND_INCREASE_IN_TRIGLYCERIDES_AND_DECREASE_IN_HIGH_DENSITY_LIPOPROTEIN_IN_PREMENOPAUSAL_WOMEN",
  "MODERATE_ANEMIA",
  "NEUROLOGICAL_ADR",
  "ACUTE_CORONARY_SYNDROME",
  "QTC_INTERVAL",
  "ESOPHAGITIS",
  "DIMINISHED_ABILITY_TO_CONCENTRATE",
  "ELEVATED_DIASTOLIC_BLOOD_PRESSURE",
  "ELEVATED_TRANSAMINASES",
  "TOXICITY-RELATED_TREATMENT_FAILURE",
  "POSTOPERATIVE_NAUSEA_AND_VOMITING",
  "VOMITING",
  "TREATMENT_INTERRUPTIONS",
  "SPEED_OF_PLATELET_RECOVERY",
  "RED_BLOOD_CELL_TRANSFUSIONS",
  "TIME_TO_ANEMIA_IN_PATIENTS_UNDERGOING_LIVING_OR_DECEASED_DONOR_KIDNEY_TRANSPLANT",
  "CNS_ADVERSE_EVENTS",
  "SEVERE_EMESIS",
  "DRUG_TOXICITY",
  "HAEMATOLOGICAL_TOXICITY",
  "THROMBOCYTOPENIA",
  "TOXIC_LIVER_DISEASE",
  "INFUSION_RELATED_REACTION",
  "CORONARY_ARTERY_DISEASE",
  "DIABETES",
  "DYSLIPIDAEMIA",
  "PHYSIOLOGICAL_SEXUAL_DISORDER",
  "EXANTHEMA",
  "ALOPECIA",
  "HYPERSENSITIVITY",
  "APPETITE_SUPPRESSION",
  "DYSKINESIA",
  "INTRACRANIAL_HEMORRHAGES",
  "TREATMENT_MODIFICATION",
  "MYELOSUPPRESSION",
  "URINARY_RETENTION",
  "CONSTIPATION",
  "ABDOMINAL_PAIN",
  "WHEEZING"
 ],
 "PK": [
  "TACROLIMUS_CONCENTRATION_TO_DOSE_RATIO_(C/D_RATIO)",
  "DOSE-ADJUSTED_AUC24",
  "ACHIEVING_OPTIMAL_TROUGH_LEVEL",
  "S-OXAZEPAM_GLUCURONIDATION_IN_HUMAN_LIVER_MICROSOMES",
  "OXAZEPAM_ORAL_CLEARANCE",
  "DIFFERENCES_IN_THE_FLUVOXAMINE_PLASMA_LEVEL_AT_50_MG/DAY",
  "AUC",
  "SERUM_CONCENTRATION",
  "CONCENTRATION/DOSE_RATIO",
  "BLOOD_CONCENTRATION/DOSAGE_RATIO",
  "6-MMPN_LEVELS",
  "PLASMA_LEVELS",
  "AREA_UNDER_THE_PLASMA_CONCENTRATION-TIME_CURVE",
  "CLEARANCE",
  "REPAGLINIDE_AUC",
  "CLOPIDOGREL_ACTIVE_METABOLITE_LEVEL",
  "ACHIEVING_TARGET_CONCENTRATIONS",
  "DOSE-ADJUSTED_BLOOD_LEVELS",
  "DOSE-ADJUSTED_TROUGH_CONCENTRATION",
  "TROUGH_CONCENTRATION",
  "AGE-RELATED_DECLINE_IN_FLECAINIDE_CLEARANCE_PATIENTS_TREATED_WITH_ORAL_FLECAINIDE_FOR_SUPRAVENTRICULAR_TACHYARRHYTHMIAS",
  "MEAN_NORTRIPTYLINE_CONCENTRATIONS_AND_NORTRIPTYLINE_CONCENTRATIONS_PER_UNIT_DOSE_OF_THE_MEDICATION",
  "ORAL_CLEARANCE_(CL/F)_OF_FLECAINIDE_IN_PATIENTS_WITH_SUPRAVENTRICULAR_TACHYARRHYTHMIA",
  "TROUGH_CONCENTRATIONS",
  "NORTRIPTYLINE_CONCENTRATIONS_CORRECTED_FOR_DOSE_AND_WEIGHT",
  "EFFLUX_OF_RHODAMINE_FROM_CD56+_NATURAL_KILLER_CELLS",
  "DOSE-ADJUSTED_TROUGH_CONCENTRATIONS",
  "S-MIRTAZAPINE_PLASMA_LEVELS_IN_NON-SMOKERS_AT_DAY_14_OF_TREATMENT",
  "SERUM_CONCENTRATIONS_OF_S(+)-MIRTAZAPINE",
  "DOSE",
  "METABOLISM",
  "REPAGLINIDE_EXPOSURE_(DECREASED_AUC_AND_INCREASED_CLEARANCE)",
  "_APPARENT_TERMINAL_ELIMINATION_HALF-LIFE",
  "ORAL_CLEARANCE_(CL)_OF_ATAZANAVIR",
  "APPARENT_TERMINAL_ELIMINATION_HALF-LIFE",
  "TROUGH_BLOOD_CONCENTRATION",
  "MEAN_SERUM_CONCENTRATIONS_OF_SERTRALINE_AND_N-DESMETHYL_SERTRALINE",
  "FLUVOXAMINE_PLASMA_CONCENTRATIONS",
  "AREA_UNDER_THE_TIME-PLASMA_CONCENTRATION_CURVE_(AUC(0-24))",
  "INHIBITION_OF_METABOLISM",
  "METABOLIC_RATIO_CIT/DCIT_VALUES_AND_MEAN_CITALOPRAM_DOSE",
  "MEAN_LOGARITHM_ESCITALOPRAM_CONCENTRATION",
  "METABOLIC_RATIO_(DEFINED_AS_RATIO_OF_OMEPRAZOLE_TO_ITS_METABOLITES)_OF_5-HYDROXYOMEPRAZOLE",
  "METABOLIC_RATIO_(DEFINED_AS_RATIO_OF_OMEPRAZOLE_TO_ITS_METABOLITES)_OF_5-HYDROXYOMEPRAZOLE_AND_R-5-HYDROXYOMEPRAZOLE",
  "AMITRIPTYLINE/NORTRIPTYLINE_RATIO_CORRECTED_FOR_DOSE_AND_WEIGHT",
  "UNBOUND_ORAL_CLEARANCE_FOR_S-WARFARIN",
  "AREA_UNDER_CURVE_(AUC)_OF_OMEPRAZOLE_RACEMATE",
  "SERUM_ANTICHOLINERGIC_ACTIVITY",
  "FORMATION_OF_METABOLITES",
  "PLASMA_CONCENTRATIONS",
  "PRAVASTATIN_PLASMA_CONCENTRATIONS_(AUC)",
  "C/D_RATIO",
  "AUC_OF_CITALOPRAM",
  "BOSENTAN_METABOLISM_IN_VITRO",
  "DOSE-ADJUSTED_TROUGH_LEVELS",
  "ACUTE_REJECTION",
  "BLOOD_CONCENTRATIONS",
  "ETRAVIRINE_CLEARANCE",
  "VENLAFAXINE_LEVELS",
  "CMAX_AND_AUC_OF_THIOL_METABOLITE",
  "MEDIAN_ORAL_CLEARANCE_OF_DOXEPIN",
  "DESIPRAMINE/2-HYDROXY-DESIPRAMINE_RATIO",
  "THE_INTRINSIC_METABOLIC_ACTIVITY_(V(MAX)/K(M))",
  "THE_MEAN_MAXIMAL_ELIMINATION_RATES_(V(MAX))",
  "DOSE-CORRECTED_PLASMA_CONCENTRATIONS",
  "IN_VITRO_INTRINSIC_CLEARANCE_OF_S-WARFARIN_WITH_THE_CDNA-EXPRESSED_R150H_PROTEIN",
  "UNBOUND_ORAL_CLEARANCE_OF_S-WARFARIN_AND_LOWER_R-_TO_S-WARFARIN_PLASMA_CONCENTRATION_RATIO",
  "PAROXETINE_SERUM_CONCENTRATION",
  "PLASMA_CONCENTRATION",
  "PLASMA_EFAVIRENZ_LEVELS",
  "TROUGH_(_R_",
  "(S)-METHADONE_PLASMA_LEVELS",
  "STEROL/BILE_ACID_METABOLITES",
  "METHOTREXATE_POLYGLUTAMATE_(MTXPG3-5)_LEVELS",
  "AREAS_UNDER_THE_SERUM_CONCENTRATION-TIME_CURVE",
  "DOSE-NORMALIZED__CMAX_AND_DOSE-NORMALIZED__AUC0TO12_H",
  "SYSTEMIC_EXPOSURE_(AUC)_AND_LOWER_ORAL_CLEARANCE_OF_FLECAINIDE",
  "IC50",
  "MEAN_OXYMORPHONE/OXYCODONE_RATIOS",
  "STEADY-STATE_PLASMA_CONCENTRATIONS_OF_DESIPRAMINE/DAILY_DOSE_OF_DESIPRAMINE/BODY_WEIGHT",
  "AREA_UNDER_THE_CURVE",
  "SERUM_CONCENTRATIONS_OF_OXYMORPHONE_AND_NOROXYMORPHONE_AND_OXYMORPHONE/OXYCODONE_RATIOS",
  "M-III:PIOGLITAZONE_AUC0-48_RATIO_AND_M-III:M-IV_AUC0-48_RATIO_IN_HEALTHY_AFRICAN-AMERICAN_VOLUNTEERS",
  "R-IBUPROFEN_METABOLISM",
  "CITALOPRAM_ORAL_CLEARANCES_OF_CITALOPRAM",
  "PAROXETINE_PLASMA_CONCENTRATION",
  "FLUOXETINE/(S)-NORFLUOXETINE_RATIO",
  "PAROXETINE_PLASMA_CONCENTRATIONS_INCREASED_DURING_THE_COURSE_OF_PREGCY",
  "DICLOFENAC/5-HYDROXYDICLOFENAC_URINARY_CONCENTRATION_RATIO",
  "RACEMIC",
  "EXPOSURE_(AREA_UNDER_THE_PLASMA_CONCENTRATION-TIME_CURVE_(AUC))_AND_DECREASED_ORAL_CLEARANCE",
  "PLASMA_4BETA-OHC/CHOL_RATIO",
  "PLASMA_AND_URINARY_RATIO_OF_METABOLITES_TRANS-3'-HYDROXYCOTININE_TO_COTININE_(3HC/COT)",
  "PAROXETINE_LEVELS",
  "PIROXICAM'S_AREA_UNDER_THE_PLASMA_CONCENTRATION-TIME_CURVE_AND_DECREASED_ORAL_CLEARANCE",
  "CLEARANCE_OF_S(+)_MIRTAZAPINE",
  "TOTAL_CLEARANCE_OF_RACEMIC_MIRTAZAPINE",
  "MEAN_LOGARITHM_ESCITALOPRAM_CONCENTRATION_AND_HIGHER_MEAN_METABOLIC_RATIO",
  "TIME_TO_ACHIEVE_THERAPEUTIC_WINDOW",
  "PLASMA_LEVEL",
  "S-CIT_SERUM_CONCENTRATIONS",
  "MEAN_ESCITALOPRAM_CONCENTRATION",
  "DEMETHYLATION_CLEARANCE_OF_DESMETHYLCITALOPRAM",
  "PLASMA_NORTRIPTYLINE",
  "SERUM_HYDRAZINE_CONCENTRATIONS",
  "SIGNIFICANTLY_HIGHER_(S)-FLUOXETINE_AND_LOWER_AND_(S)-NORFLUOXETINE_CONCENTRATIONS",
  "DOSE-CORRECTED_PLASMA_CONCENTRATIONS_OF_FLUOXETINE_AND_THE_ACTIVE_MOIETY_IN_PATIENTS_WITH_TWO_FUNCTIONAL_CYP2D6_ALLELES",
  "CONCENTRATIONS_OF_10-OH-NORTRIPTYLINE_AND_HIGHER_NORTRIPTYLINE/10-OH-NORTRIPTYLINE_RATIO",
  "PLASMA_TIMOLOL_CONCENTRATION_AND_EXCERICE_HEART_RATE_REDUCTION",
  "TOLTERODINE_EXPOSURE_AND_INCREASED_ACTIVE_METABOLITE_(5-HM)_CONCENTRATIONS",
  "GLUCURONIDATION",
  "PLASMA_METOPROLOL_CONCENTRATIONS",
  "METABOLIC_RATIOS_OF_DESIPAMINE",
  "STEADY_STATE_CONCENTRATION_PER_DOSAGE",
  "ELEVATED_PLASMA_CONCENTRATIONS",
  "PAROXETINE_SERUM_CONCENTRATIONS_(CMIN)",
  "THE_MAXIMAL_ELIMINATION_RATE_(VMAX)",
  "ELIMINATION_RATE",
  "PLASMA_METHYLMERCAPTOPURINE_NUCLEOTIDES_LEVELS",
  "HYDROXYBUPROPION_CONCENTRATIONS",
  "MEAN_AMITRIPTYLINE_CONCENTRATIONS_CORRECTED_FOR_DOSE_AND_WEIGHT",
  "CLERANCE_OF_PACLITAXEL",
  "HYDROXYBUPROPION_CONCENTRATIONS_AND_HYDROXYBUPROPION/BUPROPION_RATIO",
  "PLASMA_CONCENTRATIONS_OF_METOPROLOL",
  "AMITRIPTYLINE/(E)-10-_OH-AT_RATIO",
  "NORTRIPTYLINE/(E)-10-OH-NT_RATIO",
  "PLASMA_CONCENTRATION_OF_EFAVIRENZ",
  "PLASMA_FLUOROURACIL",
  "ATORVASTATIN_LACTONIZATION",
  "ORAL_CLEARANCE_(CL/F)_OF_OMEPRAZOLE_RACEMATE",
  "MAXIMUM_PLASMA_CONCENTRATION_OF_10-HYDROXY_NORTRIPTYLINE",
  "RELATIVE_BIOAVAILABILITY_OF_PRAVASTATIN",
  "LOWER_NEVIRAPINE_PLASMA_CONCENTRATIONS",
  "PLASMA_THIOGUANINE_NUCLEOTIDES_METABOLITES",
  "PRAVASTATIN_PLASMA_CONCENTRATIONS_(AUC)_AND_CMAX",
  "CMAX_AND_AUC_OF_VENLAFAXINE",
  "TRAMADOL_CLEARANCE_IN_CHINESE_VOLUNTEERS",
  "MEAN_PLASMA_CONCENTRATION_OF_OXYMORPHONE_AND_LOWER_MEAN_OXYMORPHONE/OXYCODONE_RATIO",
  "PAROXETINE_PLASMA_CONCENTRATION_AT_AN_ADMINISTERED_DOSE_OF_30MG/DAY",
  "SHORTER_CONTININ_HALF-LIFE",
  "ORAL_CLEARANCE_OF_CITALOPRAM",
  "_PLASMA_PAROXETINE_CONCENTRATIONS_AT_ADMINISTERED_DOSE_OF_10MG/DAY",
  "CODEINE_METABOLISM_AND_MORPHINE_AND_GLUCURONIDES_FORMATION",
  "PLASMA_LEVEL_OF_MORPHINE",
  "PLASMA_RATIO_CITALOPRAM_(CIT)/N-DESMETHYLCIT_(DCIT)",
  "EXPOSURE_TO_TIMOLOL_(HIGHER_AREA-UNDER-CURVE",
  "AUC_AND_HALF-LIFE_TIME_(T1/2)",
  "PLASMA_LEVELS_OF_MORPHINE",
  "METABOLIC_RATIO_CIT/DCIT_VALUES",
  "EXPOSURE_TO_DRUG",
  "ADJUSTED_TROUGH_CONCENTRATIONS",
  "OXYCODONE_CONSUMPTION_UP_TO_THE_12(TH)_HOUR_IN_POSTOPERATIVE_PATIENTS",
  "FLUOXETINE_PLASMA_CONCENTRATION",
  "DOSE-ADJUSTED_AREA_UNDER_THE_CONCENTRATION_VERSUS_TIME_CURVE_(AUC6-12)_LEVEL_OF_MYCOPHENOLIC_ACID",
  "DOSE-ADJUSTED_AREA_UNDER_THE_CONCENTRATION_VERSUS_TIME_CURVE_(AUC6-12)_LEVEL_OF_MYCOPHENOLIC_ACID-7-O-GLUCURONIDE",
  "_AREA_UNDER_THE_CONCENTRATION_VERSUS_TIME_CURVE_(AUC6-12)_LEVEL_OF_THE_ACYL_GLUCURONIDE_OF_MYCOPHENOLIC_ACID",
  "ANTIDEPRESSANT_SERUM_LEVELS",
  "RENAL_CLEARANCE_AND_SECRETION_CLEARANCE_OF_METFORMIN",
  "DOSE-ADJUSTED_PLASMA_LEVELS",
  "PLASMA_PREDOSE_CONCENTRATION_(CTROUGH)",
  "GLUCURONIDATION_METABOLIC_RATIOS",
  "MEAN_AREA_UNDER_THE_PLASMA_CONCENTRATION-TIME_CURVE_(AUC)_OF_DESIPRAMINE",
  "MEAN_PEAK_PLASMA_CONCENTRATION_OF_H4",
  "MIDAZOLAM_METABOLIC_RATIOS_BY_45%",
  "PLASMA_OXYMORPHONE/OXYCODONE_RATIO",
  "MEDIAN_AUC",
  "6-TG_LEVELS",
  "CREATININE_CLEARANCE",
  "BASELINE_LDL_CHOLESTEROL",
  "DOSE/WEIGHT_ADJUSTED_AUC_FOR_MIRTAZAPINE",
  "INSULIN_SECRETION_AT_BASELINE",
  "DOSE-CORRECTED_PLASMA_CONCENTRATIONS_OF_FLUOXETINE",
  "CITALOPRAM_AUC_AND_TERMINAL_ELIMINATION_HALF-LIFE",
  "MEDIAN_CONCENTRATION/DOSE_RATIO_AND_MEDIAN_PARENT_DRUG/METABOLITE_RATIO",
  "METABOLIC_RATIO",
  "METFORMIN_SECRETORY_CLEARANCE",
  "DOSE-ADJUSTED_AREA_UNDER_THE_CURVE_(AUC6-12)_OF_MYCOPHENOLIC_ACID_(MPA)",
  "LEVELS_OF_ERYTHROCYTE_6-THIOGUANINE_NUCLEOTIDE_METABOLITES",
  "HDL-C_CONCENTRATION",
  "AUC_OF_THE_S-ETIOMER_OF_CITALOPRAM_(NO_EFFECT_ON_R-CT)",
  "METABOLIC_RATIO_OF_MIDAZOLAM",
  "CHANGES_IN_MYCOPHENOLIC_ACID_EXPOSURE-RELATED_PARAMETERS_ON_DAY_7_AFTER_TRANSPLANTATION_(TREATMENT_WITH_2G_PER_DAY)",
  "PLASMA_MK-4_CONCENTRATION",
  "25%_HIGHER_MEAN_4'-DESMETHYL_OLA/OLANZAPINE_(OLA)_RATIO",
  "29%_LOWER_MEAN_4'-DESMETHYL_OLA/OLANZAPINE_(OLA)_RATIO",
  "IMPAIRED_METABOLIC_ACTIVITY",
  "_AREA_UNDER_THE_PLASMA_CONCENTRATION-TIME_CURVE",
  "PLASMA_CONCENTRATION_(P<0.001)",
  "PLASMA_CONCENTRATION_(P=0.028)",
  "BEING_A_PREDICTOR_OF_MITOTANE_PLASMA_CONCENTRATIONS_OF_AT_LEAST_14_\u039cG/ML_AFTER_3_MONTHS_OF_TREATMENT",
  "PBMC-ASSOCIATED_DRUG_CONCENTRATIONS",
  "BASELINE_CORTISOL_LEVELS",
  "INTRACELLULAR_PBMC_EXPOSURE",
  "MINIMUM_PLASMA_CONCENTRATIONS",
  "RENAL_AND_SECRETORY_CLEARANCE_OF_METFORMIN",
  "ORAL_CLEARANCE_OF_ATORVASTATIN",
  "ACCUMULATION_OF_DRUG_IN_PBMCS",
  "AREA_UNDER_PLASMA_CONCENTRATION_OF_PROPRANOLOL",
  "MID-DOSE_PLASMA_CONCENTRATIONS",
  "PLASMA_EXPOSURE",
  "MEAN_AUC",
  "INTRACELLULAR_AND_BLOOD_CONCENTRATION",
  "PLASMA_DRUG_LEVELS",
  "MITOTANE_PLASMA_CONCENTRATIONS",
  "ELIMINATION_CLEARANCE_OF_DFDU_AND_FORMATION_CLEARANCE_OF_DFDCTP",
  "FORMATION_CLEARANCE_OF_DFDCTP",
  "ELIMINATION_CLEARANCE_OF_DFDU",
  "TROUGH_BLOOD_CONCENTRATION_NORMALIZED_FOR_THE_DAILY_DOSE_(C)_PER_KILOGRAM_BODY_WEIGHT_(D)_(C/D",
  "CL_RENAL_REFERENCE_AND_LOWER_AND_CL_SEC_REFERENCE",
  "AUC_SIMVASTATIN_ACID",
  "_SERUM_R_-WARFARIN_CONCENTRATION",
  "S-WARFARIN_CLEARANCE",
  "VENLAFAXINE_CONCENTRATION_PER_UNIT_DOSE",
  "PLASMA_FREE_PHENYTOIN_CONCENTRATION",
  "MEAN_PLASMA_AUC",
  "GLUCURONIDATION_OF_NICOTINE",
  "NICOTINE_GLUCURONIDATION",
  "PROLONGED_HIGH_CONCENTRATIONS",
  "CONCENTRATION-TO-ADJUSTED_DOSE_RATIO",
  "PLASMA_CMIN_VALUES",
  "TIME_TO_REACH_STABLE_DOSE_OF_TACROLIMUS",
  "DOSE_OF_TACROLIMUS",
  "TIME_TO_REACH_STABLE_DOSE",
  "GLUCURONIDATED_METABOLITES_OF_OLANZAPINE",
  "SIGNIFICANTLY_LARGER_MEAN_AUC_OF_OSELTAMIVIR",
  "PBMC_CONCENTRATIONS",
  "DUODENAL_ABSORPTION_OF_DIGOXIN_AFTER_DIRECT_DELIVERY_TO_THE_SURFACE_OF_THE_DUODENUM_BY_ENDOSCOPE",
  "LOG_METABOLIC_RATIO_OF_AMITRIPTYLINE/NORTRIPTYLINE",
  "PLASMA_CONCENTRATIONS_OF_ROSUVASTATIN",
  "RESISTANCE",
  "BLOOD_PRESSURE",
  "INTRACELLULAR_TENOFOVIR_DIPHOSPHATE_(TFV-DP)_CONCENTRATIONS",
  "NON-INDUCIBLE_THIOTEPA_CLEARANCE_AND_DECREASED_TEPA_CLEARANCE",
  "TENOFOVIR_RENAL_CLEARANCE",
  "DOXORUBICINOL_AUC",
  "DELAYED_CORTISOL_RESPONSE_TO_STRESS",
  "9-HYDROXY-RISPERIDONE_LEVELS",
  "REPAGLINIDE_PLASMA_CONCENTRATION_(AUC)_AND_CMAX",
  "ACTIVE_MOIETY_LEVELS",
  "CMAX_AND_A_LOWER_MEAN_AUC",
  "AUC0-12",
  "DPD_ACTIVITY",
  "TROUGH_LEVELS",
  "ANTIDEPRESSANT_RESPONSE",
  "DOSE-ADJUSTED_SERUM_OLANZAPINE_N-OXIDE_CONCENTRATIONS",
  "PLASMA_CONCENTRATIONS_OF_METOPROLOL_AND_GREATER_REDUCTIONS_IN_HEART_RATE",
  "DOSE-ADJUSTED_SERUM_OLANZAPINE_CONCENTRATIONS",
  "AREA_UNDER_THE_CURVE_FROM_BASELINE_TO_THE_LAST_MEASURED_CONCENTRATION",
  "CONCENTRATION-TO-DOSE_RATIOS",
  "ERYTHROMYCIN_METABOLISM",
  "BIOAVAILABILITY",
  "BIOAVAILABILITY_(AUC",
  "ERYTHROMYCIN_BREATH_TEST",
  "BIOAVAILABILTY",
  "PLASMA_AUC",
  "EXPOSURE",
  "DISTRIBUTION_VOLUME",
  "EXPOSURE_TO_CLOPIDOGREL_ACTIVE_METABOLITE",
  "PLASMA_EFAVIRENZ_EXPOSURE_(AUC)_DURING_THE_FIRST_24_WEEKS_OF_ANTIRETROVIRAL_THERAPY",
  "PLASMA_EFAVIRENZ_EXPOSURE",
  "SERUM_URIC_ACID",
  "MEAN_PLASMA_DRUG_CONCENTRATIONS",
  "AREA_UNDER_THE_VISUAL_ANALOG_SCALE-TIME_CURVE_DURING_THE_INDUCED_STATE",
  "DOSE-ADJUSTED_TACROLIMUS_BLOOD_CONCENTRATIONS",
  "METFORMIN_UPTAKE_IN_HEK-293_CELLS_AND_REDUCTION_IN_PROTEIN_EXPRESSION_LEVELS",
  "RATIO_OF_1",
  "LEVELS_OF_CLOPIDOGREL_ACTIVE_METABOLITE",
  "CMAX_OF_THE_ACTIVE_METABOLITE",
  "RISK_OF_BEING_UNDERDOSED",
  "VMAX",
  "IN_VIVO_METABOLISM_OF_(S)-WARFARIN_BUT_NOT_(R)-WARFARIN",
  "MEAN_PEAK_CONCENTRATION_IN_PLASMA_AND_AREA_UNDER_THE_PLASMA_CONCENTRATION",
  "PLASMA_CONCENTRATIONS_OF_O-DESMETHYLTRAMADOL",
  "HIGHER_PLASMA_CONCENTRATIONS_OF_O-DESMETHYLTRAMADOL",
  "IMATINIB_CLEARANCE",
  "PITAVASTATIN_PLASMA_CONCENTRATIONS_(AUC)_AND_CMAX",
  "AUC_(P=0.002)_AND_CMAX_(P=0.003)",
  "DRAMATIC_(APPROXIMATELY_90%_AND_70%)_REDUCTION_IN_THE_METABOLISM_OF_S-MEPHENYTOIN_AND_TOLBUTAMIDE",
  "AUC_0-4_HOURS",
  "RESIDUAL_CLEARANCE_OF_INTRAVENOUS_TALINOLOL_AND_LOWER_BIOAVAILABLILTY_OF_ORALLY_ADMINISTERED_TALINOLOL",
  "MEAN_CLOMIPRAMINE_CONCENTRATIONS_CORRECTED_FOR_DOSE_AND_WEIGHT_AND_HIGHER_METABOLIC_RATIO_OF_CLOMIPRAMINE/DESMETHYLCLOMIPRAMINE",
  "HIGHER_PLASMA_CONCENTRATIONS_OF_CELECOXIB",
  "RED_BLOOD_CELL_FOLATE",
  "A_NEARLY_TRIPLED_INCREASED_PERCENTAGE_OF_ATORVASTATIN_AUC(0_-_48)_VALUES_AFTER_A_SINGLE_ORAL_DOSE_OF_RIFAMPICIN",
  "CLEARANCE_OF_DICLOXACILLIN",
  "PLASMA_CONCENTRATIONS_OF_DIFLOMOTECAN",
  "PLASMA_EXPOSURE_TO_THE_ACTIVE_METABOLITE_OF_CLOPIDOGREL",
  "CYP3A4_ACITVITY"
 ],
 "DISEASE": [
  "ALCOHOL_ABUSE",
  "HEMORRHAGE",
  "MYALGIA",
  "DRUG_REACTION_WITH_EOSINOPHILIA_AND_SYSTEMIC_SYMPTOMS",
  "SEVERE_CUTANEOUS_ADVERSE_REACTIONS",
  "DRUG_TOXICITY",
  "INFECTIOUS_DISEASE",
  "STOMATITIS",
  "TOXIC_EPIDERMAL_NECROLYSIS",
  "STEVENS-JOHNSON_SYNDROME",
  "MYOCARDIAL_INFARCTION",
  "DIZZINESS",
  "MUCOSITIS",
  "NAUSEA",
  "GASTRIC_PH",
  "THROMBOCYTOPENIA",
  "CHRONIC_KIDNEY_FAILURE",
  "EXANTHEMA",
  "DEATH",
  "TOXIC_LIVER_DISEASE",
  "HYPOGLYCEMIA",
  "NEUROTOXICITY_SYNDROMES",
  "ASPIRIN-INDUCED_ASTHMA",
  "ACUTE_CELLULAR_REJECTION",
  "VOMITING",
  "DRUG_HYPERSENSITIVITY",
  "CORONARY_DISEASE",
  "KIDNEY_DISORDER",
  "HYPERBILIRUBINEMIA",
  "NEUTROPENIA",
  "DEPRESSION",
  "FATIGUE",
  "PSYCHOTIC_DISORDER",
  "THROMBOTIC_DISEASE",
  "MACULOPAPULAR_EXANTHEMA",
  "DELAYED_GRAFT_FUNCTION",
  "BREAST_NEOPLASMS",
  "NEPHROTOXICITY",
  "PAIN",
  "TOBACCO_USE_DISORDER",
  "DRUG-INDUCED_LIVER_INJURY",
  "DIARRHEA",
  "INTERSTITIAL_FIBROSIS",
  "HYPERTENSION",
  "BRAIN_NEOPLASMS",
  "CARCINOMA",
  "ABORTION",
  "ANEMIA",
  "ASTHMA",
  "PERIPHERAL_NERVOUS_SYSTEM_DISEASES",
  "DEHYDRATION",
  "LEUKOPENIA",
  "TRANSPLANT_REJECTION",
  "HAND-FOOT_SYNDROME",
  "WEIGHT_GAIN",
  "HEART_FAILURE",
  "RESPIRATORY_TRACT_INFECTIONS",
  "PEPTIC_ULCER_DISEASE",
  "DISORDER_OF_FACIAL_SKELETON",
  "ANXIETY_DISORDERS",
  "HYPERPROLACTINEMIA",
  "HYPOTENSIVE_DISORDER",
  "AGRANULOCYTOSIS",
  "SUICIDE",
  "RECURRENCE",
  "INFLAMMATION",
  "SUBSTANCE-RELATED_DISORDERS",
  "INSULIN_RESISTANCE",
  "METABOLIC_SYNDROME",
  "HEMOLYSIS",
  "ASTHENIA",
  "DRUG_RESISTANCE",
  "RHEUMATOID_ARTHRITIS",
  "BRADYCARDIA",
  "VIRUS_DISEASES",
  "HYPERTRIGLYCERIDEMIA",
  "OSTEONECROSIS",
  "COUGH",
  "POSTOPERATIVE_NAUSEA_AND_VOMITING",
  "HEPATITIS",
  "OTOTOXICITY",
  "OLIGOSPERMIA",
  "HYPOKALEMIA",
  "BREAST_TENDERNESS",
  "VAGINAL_DRYNESS",
  "LEUKEMIA",
  "EVENT-FREE_SURVIVAL",
  "OVERALL_SURVIVAL",
  "CORONARY_ARTERY_DISEASE",
  "HEMATOLOGIC_DISORDER",
  "LUNG_NEOPLASMS",
  "PROSTATIC_NEOPLASMS",
  "SEIZURES",
  "PNEUMONITIS",
  "COCAINE_DEPENDENCE",
  "OPIOID-RELATED_DISORDERS",
  "MUSCULAR_DISEASES",
  "OSTEOPOROSIS",
  "HEROIN_DEPENDENCE",
  "DIABETES",
  "EDEMA",
  "TARDIVE_DYSKINESIA",
  "MYELOSUPPRESSION",
  "COLONIC_NEOPLASMS",
  "CENTRAL_NERVOUS_SYSTEM_DISORDER",
  "PROGRESSION-FREE_SURVIVAL",
  "GASTROINTESTINAL_HEMORRHAGE",
  "VENTRICULAR_FIBRILLATION",
  "METABOLIC_BONE_DISORDER",
  "IRON_OVERLOAD",
  "VENOUS_THROMBOSIS",
  "STROKE",
  "CARDIOMYOPATHIES",
  "DIABETES_MELLITUS",
  "ALOPECIA",
  "SCHIZOPHRENIA",
  "HEPATIC_VENO-OCCLUSIVE_DISEASE",
  "PROTEINURIA",
  "ATRIAL_FIBRILLATION",
  "MAJOR_DEPRESSIVE_DISORDER",
  "PARKINSON_DISEASE",
  "MALIGT_HYPERTHERMIA",
  "FATTY_LIVER_DISEASE",
  "RHABDOMYOLYSIS",
  "KIDNEY_FAILURE",
  "OBESITY",
  "CROHN_DISEASE",
  "DYSKINESIAS",
  "HALLUCINATIONS",
  "VENOUS_THROMBOEMBOLISM",
  "MULTIPLE_SCLEROSIS",
  "HEADACHE",
  "ISCHEMIA",
  "DRY_MOUTH",
  "FRACTURES",
  "GINGIVAL_HYPERPLASIA",
  "TORSADES_DE_POINTES",
  "EPILEPSY",
  "CARDIOVASCULAR_DISEASE",
  "SLEEP_DISORDERS",
  "CARDIOTOXICITY",
  "CARDIAC_RHYTHM_DISEASE",
  "ACUTE_CORONARY_SYNDROME",
  "SUDDEN_INFANT_DEATH",
  "METHAMPHETAMINE_DEPENDENCE",
  "CHRONIC_OBSTRUCTIVE_PULMONARY_DISEASE",
  "BIPOLAR_DISORDER",
  "HOT_FLASHES",
  "NEURAL_TUBE_DEFECTS",
  "SYNCOPE",
  "ORTHOSTATIC_HYPOTENSION",
  "GRAFT_VS_HOST_DISEASE",
  "ATTENTION_DEFICIT_DISORDER_WITH_HYPERACTIVITY",
  "COLORECTAL_NEOPLASMS",
  "LIVER_FAILURE",
  "PEPTIC_ULCER_HEMORRHAGE",
  "PERIPHERAL_VASCULAR_DISEASES",
  "THERAPY-RELATED_ACUTE_MYELOID_LEUKEMIA_(T-AML)",
  "HEADACHE_DISORDERS",
  "SUBSTANCE_WITHDRAWAL_SYNDROME",
  "ADENOMA",
  "CYSTITIS",
  "FEVER",
  "HYPERLIPIDEMIAS",
  "LYMPHOPENIA",
  "UROLOGIC_NEOPLASMS",
  "HYPERCHOLESTEROLEMIA",
  "MUSCULOSKELETAL_PAIN",
  "ENDOMETRIAL_NEOPLASMS",
  "PLATELET_AGGREGATION",
  "CYSTIC_FIBROSIS_PULMONARY_EXACERBATION",
  "CONSTIPATION",
  "HEPATITIS_C_VIRUS_INFECTION",
  "HYPERGLYCEMIA",
  "SICKLE_CELL_PAIN_CRISIS",
  "JAUNDICE"
 ],
 "EFFICACY": [
  "KIDNEY_TUBULAR_NECROSIS",
  "RELAPSE",
  "MINIMAL_RESIDUAL_DISEASE",
  "STRONGER_AGGREAGTION",
  "CLOPIDOGREL_RESISTANCE",
  "NET_DECREASE_IN_AA-INDUCED_PLATELET_AGGREGATION_AFTER_ASPIRIN_TREATMENT",
  "KIDNEY_DISORDER",
  "ALCOHOL_ABUSE",
  "RESPONSE_(HEART-RATE_LOWERING)",
  "REDUCED_PROGRESSION-FREE_SURVIVAL",
  "HEART_TRANSPLANTATION",
  "DEATH",
  "BRONCHODILATOR_RESPONSE_(FEV1)",
  "CORONARY_RESTENOSIS",
  "DISEASE_PROGRESSION",
  "POOR_RESPONSE",
  "TUMOR_RESPONSE_RATE",
  "ONE_YEAR_PROGRESSION_FREE_SURVIVAL",
  "NUMERICAL_RATING_SCALE_(NRS)_SCORE_FOR_PAIN_DURING_PAINFUL_PROCEDURE",
  "OVERALL_MEAN_NUMERICAL_RATING_SCALE_(NRS)_SCORE_FOR_PAIN",
  "CHANGE_IN_TOTAL_CHOLESTEROL",
  "TIME_TO_PROGRESSION",
  "RISE_IN_CD4-CELL_COUNT",
  "FAVORABLE_VIROLOGIC_RESPONSES",
  "CHANGE_IN_HDL-CHOLESTEROL",
  "ACUTE_REJECTION",
  "TIME_TO_THE_FIRST_INR_WITHIN_THE_THERAPEUTIC_RANGE",
  "IMPROVEMENTS_IN_NEUROVEGETATIVE_SYMPTOMS",
  "POSITIVE_RELATIONSHIP_BETWEEN_OLANZAPINE_PLASMA_LEVELS_AND_POSITIVE_SYMPTOM_REDUCTION_COMPARED_TO_SUBJECTS_WITH_THE_GG_GENOTYPE",
  "REDUCTION_IN_TOTAL_CHOLESTEROL_AND_LDL-CHOLESTEROL",
  "PERCENTAGE_CHANGE_IN_LDL-CHOLESTEROL_LEVELS",
  "CARDIOVASCULAR_DEATH",
  "CLINICAL_RESPONSE",
  "RESISTANCE",
  "INDUCTION_FAILURE",
  "REDUCTION_IN_LDLC",
  "BRIEF_PSYCHIATRIC_RATING_SCALE_SCORES",
  "CRAVING",
  "REDUCTION_IN_DNA_DAMAGE",
  "GREATER_POSITIVE_SYMPTOM_IMPROVEMENT_AND_POSITIVE_SYMPTOM_REMISSION",
  "POSITIVE_RESPONSE",
  "TREATMENT_RESPONSE",
  "FREQUENCY_OF_RESCUE_ANALGESIC_ADMINISTRATION",
  "RESPONSE_BASE_ON_DISEASE_ACTIVITY_SCORE_IN_44_JOINTS_IMPROVEMENT_AT_6_MONTHS_OF_TREATMENT",
  "_DISEASE_ACTIVITY_AS_ASSESSED_BY_THE_PHYSICIAN",
  "PROSTATE_CANCER-SPECIFIC_MORTALITY",
  "TIME_IN_THERAPEUTIC_RANGE_OF_INR_(TTR)",
  "COMPLETE_RESPONSE_RATE",
  "IMPROVEMENT_IN_BONE_MINERAL_DENSITY",
  "RESPONSE_(SVR)_TO_INTERFERON_MONOTHERAPY_IN_HCV_GENOTYPE_1_PATIENTS",
  "RESPONSE_(SVR)_IN_HCV_GENOTYPE_1_PATIENTS",
  "OVERALL_SURVIVAL_(OS)_TIME",
  "RESPONSE_RATE",
  "OVERALL_SURVIVAL_AND_TIME-TO-TREAT_FAILURE",
  "HYPERLIPIDEMIAS",
  "CHANGES_IN_FEV1",
  "TUMOR_RESPONSE",
  "RESIDUAL_PLATELET_REACTIVITY",
  "PERCENT_CHANGE_IN_FEV",
  "GLUCOCORTICOID_RESPONSIVENESS",
  "SUBSTANCE_WITHDRAWAL_SYNDROME",
  "IMPROVEMENT_IN_LEFT_VENTRICULAR_FUNCTION_(LVEF)",
  "CRYOGLOBULINEMIA",
  "SIGNIFICANTLY_GREATER_IMPROVEMENT_IN_LEFT_VENTRICULAR_EJECTION_FRACTION_(LVEF)",
  "MEAN_CHANGE_IN_FEV",
  "IMPROVEMENT_IN_LEFT_VENTRICULAR(LV)_REMODELING_AND_GREATER_INCREASE_IN_LVEF_(LEFT_VENTRICULAR_EJECTION_FRACTION)",
  "COLLAGEN_INDUCED_PLATELET_AGGREGATION_AFTER_ASPIRIN_OR_DUAL_ANTIPLATELET_THERAPY_(DAPT)_ADMINISTRATION",
  "HAMD_SCORES",
  "LONGER_MEDIAN_PROGRESSION-FREE_SURVIVAL_TIME",
  "ABSTINENCE",
  "TIME_TO_TUMOR_RECURRENCE",
  "VIROLOGICAL_RESPONSE",
  "CARDIAC_EVENTS",
  "SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)_AND_CHANGES_IN_VIRAL_LOAD_AFTER_4_WEEKS_OF_TREATMENT",
  "RAPID_VIRAL_RESPONSE_(RVR)_TO_PEG-IFN/RIBAVIRIN_THERAPY_AT_4_WEEKS_IN_HCV_GENOTYPE_3_PATIENTS",
  "IMMUNOLOGICAL_FAILURE",
  "MEDIAN_SURVIVAL_TIME_(MST)",
  "PRIMARY_OUTCOME",
  "MEDIAN_SURVIAL_TIME",
  "EXACERBATIONS",
  "UNCONTROLLED_ASTHMA",
  "COMPLETE_PATHOLOGIC_RESPONSE",
  "PHYSICAL_AND_LIFE_WELL-BEING_QUALITY_OF_LIFE_(QOL)_SCALES",
  "OVER-ANTICOAGULATION",
  "RENAL_TRANSPLANT_FAILURE",
  "PROBABILITY_OF_ANTIEPILEPTIC_DRUG_RESPONSE",
  "RELAPSE_IN_THE_CENTRAL_NERVOUS_SYSTEM",
  "MYOCARDIAL_INFARCTION",
  "STROKE",
  "SEDATION",
  "ANTIDEPRESSANT_RESPONSE",
  "SLOWER_ANALGESIC_ONSET_IN_EUROPEAN_AMERICANS_UNDERGOING_ORAL_SURGERY",
  "APOLIPOPROTEIN_A1_AND_C3",
  "VOL%_END-TIDAL_SEVOFLURANE_CONCENTRATION",
  "PLATELET_AGGREGATION_AFTER_STIMULI_WITH_ADENOSINE_DIPHOSPHATE",
  "HIGHER_FENTANYL_DOSE_REQUIREMENT_TO_ACHIEVE_ADEQUATE_PAIN_RELIEF_IN_CHINESE_WOMEN_UNDERGOING_GYNECOLOGIC_SURGERY",
  "HIGHER_RESPONSIVENESS_TO_OPIOIDS_AND_REQUIRED_LESS_ANALGESIC_DRUGS_IN_LABORING_WOMEN",
  "LESS_PAIN_CONTROL_IN_JAPANESE_PATIENTS_UNDERGOING_PAINFUL_OROFACIAL_COSMETIC_SURGERY",
  "THE_LACK_OF_ASPIRIN_EFFECT",
  "24-H_EXCRETION_OF_CHLORIDE_AND_POTASSIUM",
  "NONRESPONSE_TO_METHADONE_MAINTECE_TREATMENT",
  "24-H_EXCRETION_OF_CALCIUM_AND_DECREASED_URINARY_VOLUME",
  "INCREASED_RISK_OF_BEING_NONRESPONDERS",
  "CORONARY_ARTERY_DISEASE",
  "BENEFIT",
  "ASPIRIN-DEPRESSED_THROMBIN_GENERATION_AND_PROLONGED_BLEEDING_TIME_AFTER_ASPIRIN",
  "INHIBITION_OF_FXIII_ACTIVATION_BY_ASPIRIN",
  "REDUCTION_IN_LUMINAL_DIAMETER",
  "LOWER_LEVELS_OF_TRANSTHYRETIN_PRECUROR",
  "NON-RESPONSE_TO_ASPIRIN",
  "3-YEAR_EVENT_FREE_SURVIVAL",
  "8.3%_HIGHER_MEAN_DAILY_COUMARIN_DOSE_TO_REACH_A_STABLE_INTERNATIONAL_NORMALIZED_RATIO_(INR)",
  "ADP-INDUCED_PLATELET_AGGREGATION",
  "IMPROVED_LEFT_VENTRICULAR_EJECTION_FRACTION",
  "PLATELET_INHIBITION_BY_ASPIRIN",
  "FATAL_CORONARY_DISEASE_OR_NONFATAL_MYOCARDIAL_INFARCTION",
  "RESPONSE_RATE_AFTER_10_WEEKS_OF_PIOGLITAZONE_TREATMENT",
  "SOCIAL_AND_CLINICAL_NEEDS",
  "RESPONSE_AT_4_WEEKS_AFTER_THE_INITIATION_OF_TREATMENT",
  "BONE_DENSITY",
  "TRANSIENT_ISCHEMIC_ATTACK",
  "RELAPSE_FREE_TIME",
  "CARDIOVASCULAR_EVENTS",
  "DYING",
  "FIBRIN_CLOT_FORMATION_TIME",
  "BEING_SENSITIVE_TO_CAFFEINE",
  "DECREASED_CHANCE_OF_ACHIEVING_6_MONTH_ABSTINENCE_IN_THE_PLACEBO_GROUP",
  "PERCENTAGE_CHANGE_IN_HDL-C_LEVELS",
  "RESIDUAL_ON-CLOPIDOGREL_PLATELET_REACTIVITY",
  "PROGRESSION_FREE_SURVIVAL_(PFS)_TIME",
  "CHEMORESISTANCE",
  "REDUCTION_IN_AMBULATORY_BLOOD_PRESSURE",
  "RESISTANT_RELAPSE",
  "REDUCTION_IN_DIASTOLIC_BLOOD_PRESSURE",
  "RECURRENCE_OF_DISEASE",
  "INHIBITION_OF_PLATELET_AGGREGATION_AND_POOR-RESPONDER_STATUS",
  "NALTREXONE-INDUCED_BLUNTING_OF_ALCOHOL_STIMULATION_AND_ALCOHOL_CRAVING",
  "IMPROVED_RESPONSE",
  "BASELINE_MEAN_ARTERIAL_BLOOD_PRESSURE",
  "PLATELET_INHIBITION",
  "INCREASED_CHANCE_OF_ACHIEVING_6_MONTH_ABSTINENCE_IF_PRESCRIBED_NRT_(NICOTIENE_REPLACEMENT_THERAPY)",
  "RESPONSE_TIME",
  "RECURRENCE_OF_BREAST_CANCER",
  "REDUCTION_IN_OFFICE_DIASTOLIC_BLOOD_PRESSURE",
  "DOSE-ADJUSTED_TACROLIMUS_BLOOD_CONCENTRATION",
  "ELEVATED_SYSTOLIC_BLOOD_PRESSURE",
  "ELEVATED_DIASTOLIC_BLOOD_PRESSURE",
  "REDUCTION_IN_WHOLE_DAY_AMBULATORY_BLOOD_PRESSURE",
  "SVR_(SUSTAINED_VIROLOGICAL_RESPONSE)",
  "RECURRENCE-FREE_SURVIVAL",
  "LESS_DECREASE_IN_THE_PLATELET_REACTIVITY_AFTER_600_MG_OF_CLOPIDOGREL",
  "ANTIPLATELET_EFFECT_TO_A_300_MG_CLOPIDOGREL_LOADING-DOSE_UP_TO_24_H_FOLLOWING_INTERVENTION",
  "_ON-TREATMENT_ADP-INDUCED_PLATELET_AGGREGATION",
  "ON-TREATMENT_ADP-INDUCED_PLATELET_AGGREGATION",
  "PLATELET_REACTIVITY_INDEX_(PRI)_AT_4_H_AFTER_THE_DOSING",
  "HIGHER_P2Y12_REACTION_UNITS_(PRU)_AND_LOWER_PERCENT_INHIBITION",
  "NON-RESPONSE_TO_CLOPIDOGREL",
  "PLATELET_RESPONSIVENESS_TO_CLOPIDOGREL",
  "REDUCED_GP_IIB/IIIA_ACTIVATION_AND_LOWER_PLATELET_ACTIVATION",
  "THE_TIME_TO_ACHIEVE_A_FIRST_INR_WITHIN_THE_THERAPEUTIC_RANGE",
  "SHORTER_TIME_TO_HAVE_OVER-ANTICOAGULATION_(INR_>4)_RISK",
  "AVERAGE_DAILY_DOSE_DURING_THE_FIRST_PERIOD_OF_STABILITY",
  "CHANGE_IN_FORCED_EXPIRATORY_VOLUME_IN_1_S_(FEV1)",
  "PLATELET_AGGREGATION_VALUES",
  "GREATER_PLATELET_INHIBITION_2_H_AFTER_A_600-MG_DOSE",
  "PLATELET_INHIBITION_7H_AFTER_A_CLOPIDOGREL_600-MG_LOADING_DOSE",
  "DIFFERENCE_IN_POSTPRANDIAL_PLASMA_GLUCOSE_(BEFORE_AND_AFTER_DRUG_TREATMENT)",
  "DIFFERENCE_IN_FASTING_PLASMA_GLUCOSE_(BEFORE_AND_AFTER_DRUG_TREATMENT)",
  "HIGH-ON_CLOPIDOGREL_PLATELET_REACTIVITY",
  "ANTIPLATELET_EFFECT",
  "HIGH_POST-TREATMENT_PLATELET_REACTIVITY",
  "CLOPIDOGREL_INHIBITION_OF_ADP-INDUCED_PLATELET_AGGREGATION",
  "END_OF_TREATMENT_ABSTINENCE",
  "SUBOPTIMAL_REPERFUSION_(POST-PCI_TIMI_FLOW_<3)",
  "ANTI-VEGF_INJECTIONS",
  "SUBCLINICAL_INTRA-STENT_THROMBUS",
  "SERUM_OSTEOCALCIN",
  "INADEQUATE_INHIBITION_OF_PLATELET_ACTIVITY",
  "A_22%_INCREASE_IN_THERAPEUTIC_WARFARIN_DOSE_REQUIREMENT_AFTER_ADJUSTMENT_FOR_CLINICAL_AND_GENETIC_COVARIATES_IN_HISPANIC-AMERICANS",
  "A_34%_INCREASE_IN_THERAPEUTIC_WARFARIN_DOSE_REQUIREMENT_WHILE_HOLDING_CLINICAL_AND_GENETIC_PREDICTORS_CONSTANT_IN_HISPANIC-AMERICANS",
  "MEAN_PEAK_INR_DURING_WEEK_1_OF_WARFARIN_THERAPY",
  "HDL-CHOLESTEROL",
  "SURVIVAL_RATE",
  "LYMPH_NODE_METASTASES",
  "POOR-RESPONSE_TO_CLOPIDOGREL",
  "BLOOD_PRESSURE_(BP)_REDUCTION",
  "MYOCARDIAL_ISCHEMIA",
  "REDUCED_WARFARIN_DOSE_IN_AFRICAN_AMERICANS",
  "OCCURRENCE_OF_BREAST_CANCER_DURING_SERM_(SELECTIVE_ESTROGEN_RECEPTOR_MODULATORS)_THERAPY",
  "INSUFFICIENT_ANTIPLATELET_RESPONSE_TO_CLOPIDOGREL",
  "5_YEAR_SURVIVAL",
  "OPIOIDS_RESPONSE",
  "EFFICACT_AS_MEASURED_BY_LOWER_PAIN_RELIEF_TO_OPIOIDS",
  "REDUCTION_IN_SBP",
  "REDUCTION_IN_COX-1_INHIBITION_AND_DEPRESSION_OF_THE_URINARY_THROMBOXANE_METABOLITE",
  "REDUCTION_IN_COX-1_INHIBITION",
  "ABSOLUTE_MEAN_BLOOD_PRESSURE",
  "EMERGING_VIRAL_DRUG_RESISTANCE",
  "PROTECTION_FROM_DRUG_RESISTANCE",
  "IC-50",
  "PLATELET_INHIBITION_AFTER_A_CLOPIDOGREL_600-MG_LOADING_DOSE",
  "RATES_OF_TARGET_LESION_REVASCULARIZATION_AND_MAJOR_ADVERSE_CARDIOVASCULAR_EVENTS",
  "TO_BE_CLASSIFIED_AS_CLOPIDOGREL_POOR_RESPONDERS",
  "CLOPIDOGREL_POOR_RESPONSE",
  "STAYING_IN_REMISSION",
  "SMOKING_ABSTINENCE_WITHIN_SLOW_NICOTINE_METABOLIZERS",
  "REDUCTION_OF_LDL_CHOLESTEROL",
  "PAIN_RELIEF",
  "PHARMACODYNAMIC_RESPONSE",
  "A_DECREASE_IN_VISUAL_ANALOG_SCALE_>30MM_WITHIN_6_HOURS",
  "REACHING_TARGET_CHOLESTEROL_LEVELS",
  "MEAN_SPINAL_BONE_MINERAL_DENSITY_CHANGES",
  "PLATELET_ACTIVATION_RESPONSE_TO_ADP",
  "REDUCTION_IN_MEAN_BLOOD_PRESSURE",
  "IMPROVEMENT_IN_ANXIETY-DEPRESSION_SYMPTOMS",
  "REDUCTION_IN_MEAN_ARTERIAL_PRESSURE",
  "EMERGENCIES",
  "PAIN"
 ]
}